Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: A 4-week open-label, parallel-group study of major depressive disorder

Kei Nagao, Taro Kishi, Masatsugu Moriwaki, Kiyoshi Fujita, Shigeki Hirano, Yoshio Yamanouchi, Toshihiko Funahashi, Nakao Iwata

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

No studies have compared mirtazapine with duloxetine in patients with major depressive disorder (MDD). Fifty-six patients were nonrandomly assigned to a 4-week treatment with either 15 to 45 mg/day of mirtazapine (n = 22) or 20 to 60 mg/day of duloxetine (n=34). The primary efficacy measurements were the Hamilton Rating Scale for Depression (HRSD) and the Montgomery-Åsberg Depression 6-point Rating Scale (MADRS) scores. The second efficacy measurements were the response and remission rates of treatment. Tolerability assessments were also performed. Fifty-six patients (43 male; age, 43.6 years) were recruited. There was no significant difference in the discontinuation rate between the mirtazapine and duloxetine treatment groups (P = 0.867). Both mirtazapine and duloxetine significantly improved the HRSD and MADRS scores from baseline (P 0.0001-0.0004). While mirtazapine was superior to duloxetine in the reduction of HRSD scores (P = 0.0421), there was no significant change in MADRS scores in terms of between-group differences (P = 0.171). While more somnolence was observed with mirtazapine (P = 0.0399), more nausea was associated with duloxetine (P = 0.0089). No serious adverse events were observed for either antidepressant. Mirtazapine and duloxetine were safe and well-tolerated treatments for Japanese patients with MDD. Double-blind controlled studies are needed to further explore the efficacy and safety of mirtazapine and duloxetine in Japanese patients with MDD.

Original languageEnglish
Pages (from-to)781-786
Number of pages6
JournalNeuropsychiatric Disease and Treatment
Volume9
DOIs
Publication statusPublished - 04-06-2013

Fingerprint

Major Depressive Disorder
Japan
Depression
Duloxetine Hydrochloride
mirtazapine
Therapeutics
Double-Blind Method
Nausea
Antidepressive Agents
Safety

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Nagao, Kei ; Kishi, Taro ; Moriwaki, Masatsugu ; Fujita, Kiyoshi ; Hirano, Shigeki ; Yamanouchi, Yoshio ; Funahashi, Toshihiko ; Iwata, Nakao. / Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan : A 4-week open-label, parallel-group study of major depressive disorder. In: Neuropsychiatric Disease and Treatment. 2013 ; Vol. 9. pp. 781-786.
@article{ee8b236205784ca7b7a5f8db06464b2d,
title = "Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: A 4-week open-label, parallel-group study of major depressive disorder",
abstract = "No studies have compared mirtazapine with duloxetine in patients with major depressive disorder (MDD). Fifty-six patients were nonrandomly assigned to a 4-week treatment with either 15 to 45 mg/day of mirtazapine (n = 22) or 20 to 60 mg/day of duloxetine (n=34). The primary efficacy measurements were the Hamilton Rating Scale for Depression (HRSD) and the Montgomery-{\AA}sberg Depression 6-point Rating Scale (MADRS) scores. The second efficacy measurements were the response and remission rates of treatment. Tolerability assessments were also performed. Fifty-six patients (43 male; age, 43.6 years) were recruited. There was no significant difference in the discontinuation rate between the mirtazapine and duloxetine treatment groups (P = 0.867). Both mirtazapine and duloxetine significantly improved the HRSD and MADRS scores from baseline (P 0.0001-0.0004). While mirtazapine was superior to duloxetine in the reduction of HRSD scores (P = 0.0421), there was no significant change in MADRS scores in terms of between-group differences (P = 0.171). While more somnolence was observed with mirtazapine (P = 0.0399), more nausea was associated with duloxetine (P = 0.0089). No serious adverse events were observed for either antidepressant. Mirtazapine and duloxetine were safe and well-tolerated treatments for Japanese patients with MDD. Double-blind controlled studies are needed to further explore the efficacy and safety of mirtazapine and duloxetine in Japanese patients with MDD.",
author = "Kei Nagao and Taro Kishi and Masatsugu Moriwaki and Kiyoshi Fujita and Shigeki Hirano and Yoshio Yamanouchi and Toshihiko Funahashi and Nakao Iwata",
year = "2013",
month = "6",
day = "4",
doi = "10.2147/NDT.S43600",
language = "English",
volume = "9",
pages = "781--786",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan : A 4-week open-label, parallel-group study of major depressive disorder. / Nagao, Kei; Kishi, Taro; Moriwaki, Masatsugu; Fujita, Kiyoshi; Hirano, Shigeki; Yamanouchi, Yoshio; Funahashi, Toshihiko; Iwata, Nakao.

In: Neuropsychiatric Disease and Treatment, Vol. 9, 04.06.2013, p. 781-786.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan

T2 - A 4-week open-label, parallel-group study of major depressive disorder

AU - Nagao, Kei

AU - Kishi, Taro

AU - Moriwaki, Masatsugu

AU - Fujita, Kiyoshi

AU - Hirano, Shigeki

AU - Yamanouchi, Yoshio

AU - Funahashi, Toshihiko

AU - Iwata, Nakao

PY - 2013/6/4

Y1 - 2013/6/4

N2 - No studies have compared mirtazapine with duloxetine in patients with major depressive disorder (MDD). Fifty-six patients were nonrandomly assigned to a 4-week treatment with either 15 to 45 mg/day of mirtazapine (n = 22) or 20 to 60 mg/day of duloxetine (n=34). The primary efficacy measurements were the Hamilton Rating Scale for Depression (HRSD) and the Montgomery-Åsberg Depression 6-point Rating Scale (MADRS) scores. The second efficacy measurements were the response and remission rates of treatment. Tolerability assessments were also performed. Fifty-six patients (43 male; age, 43.6 years) were recruited. There was no significant difference in the discontinuation rate between the mirtazapine and duloxetine treatment groups (P = 0.867). Both mirtazapine and duloxetine significantly improved the HRSD and MADRS scores from baseline (P 0.0001-0.0004). While mirtazapine was superior to duloxetine in the reduction of HRSD scores (P = 0.0421), there was no significant change in MADRS scores in terms of between-group differences (P = 0.171). While more somnolence was observed with mirtazapine (P = 0.0399), more nausea was associated with duloxetine (P = 0.0089). No serious adverse events were observed for either antidepressant. Mirtazapine and duloxetine were safe and well-tolerated treatments for Japanese patients with MDD. Double-blind controlled studies are needed to further explore the efficacy and safety of mirtazapine and duloxetine in Japanese patients with MDD.

AB - No studies have compared mirtazapine with duloxetine in patients with major depressive disorder (MDD). Fifty-six patients were nonrandomly assigned to a 4-week treatment with either 15 to 45 mg/day of mirtazapine (n = 22) or 20 to 60 mg/day of duloxetine (n=34). The primary efficacy measurements were the Hamilton Rating Scale for Depression (HRSD) and the Montgomery-Åsberg Depression 6-point Rating Scale (MADRS) scores. The second efficacy measurements were the response and remission rates of treatment. Tolerability assessments were also performed. Fifty-six patients (43 male; age, 43.6 years) were recruited. There was no significant difference in the discontinuation rate between the mirtazapine and duloxetine treatment groups (P = 0.867). Both mirtazapine and duloxetine significantly improved the HRSD and MADRS scores from baseline (P 0.0001-0.0004). While mirtazapine was superior to duloxetine in the reduction of HRSD scores (P = 0.0421), there was no significant change in MADRS scores in terms of between-group differences (P = 0.171). While more somnolence was observed with mirtazapine (P = 0.0399), more nausea was associated with duloxetine (P = 0.0089). No serious adverse events were observed for either antidepressant. Mirtazapine and duloxetine were safe and well-tolerated treatments for Japanese patients with MDD. Double-blind controlled studies are needed to further explore the efficacy and safety of mirtazapine and duloxetine in Japanese patients with MDD.

UR - http://www.scopus.com/inward/record.url?scp=84878746810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878746810&partnerID=8YFLogxK

U2 - 10.2147/NDT.S43600

DO - 10.2147/NDT.S43600

M3 - Article

C2 - 23766648

AN - SCOPUS:84878746810

VL - 9

SP - 781

EP - 786

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -